VIEWPOINT AND COMMENTARY
There Is Plenty of Room for Cardiac Resynchronization Therapy Devices Without Back-Up Defibrillators in the Electrical Treatment of Heart Failure
J. Claude Daubert, MD, FACC*,
Christophe Leclercq, MD, PhD and
Philippe Mabo, MD
Department of Cardiology, Centre Hospitalier Universitaire, Rennes, France
Manuscript received August 4, 2005;
accepted August 9, 2005.
* Reprint requests and correspondence: Dr. Jean-Claude Daubert, Centre Hospitalier Universitaire, Department of Cardiology, F-35000 Rennes, France. (Email: jean-claude.daubert{at}chu-rennes.fr).
Patients with chronic heart failure might benefit from electrical therapy with a view to resynchronize the heart and improve its mechanical performance by cardiac resynchronization therapy (CRT) or to prevent the risk of sudden death by automatic defibrillation. These two therapies can be applied separately or with a combined device, the biventricular implantable cardioverter-defibrillator (CRT-D). There is currently no strong scientific evidence indicating that a CRT-D must be offered to all candidates for CRT. Plain common sense should limit the prescription of these costly devices for patients in need of secondary prevention or for younger patients without major comorbidities. The preferential choice of CRT pacemakers in the remainder of patients is currently a logical one.
|
Abbreviations and Acronyms
| | ARR = absolute risk reduction | | CHF = chronic heart failure | | CRT-D = cardiac resynchronization therapy by biventricular defibrillation | | CRT-P = pacemaker for cardiac resynchronization therapy | | EF = ejection fraction | | ICD = implantable cardioverter-defibrillator | | LV = left ventricular | | NYHA = New York Heart Association | | RRR = relative reduction in the risk of overall mortality |
|
This article has been cited by other articles:

|
 |

|
 |
 
N. Bogale, S. Priori, A. Gitt, M. Alings, C. Linde, K. Dickstein, and on behalf of the Scientific Committee, National co
The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume
Europace,
October 1, 2011;
13(10):
1445 - 1453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Kramer, D. W. Brock, and U. B. Tedrow
Informed Consent in Cardiac Resynchronization Therapy: What Should Be Said?
Circ Cardiovasc Qual Outcomes,
September 1, 2011;
4(5):
573 - 577.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. van Veldhuisen, A. H. Maass, S. G. Priori, P. Stolt, I. C. van Gelder, K. Dickstein, and K. Swedberg
Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008
Eur J Heart Fail,
December 1, 2009;
11(12):
1143 - 1151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Dickstein, N. Bogale, S. Priori, A. Auricchio, J. G. Cleland, A. Gitt, T. Limbourg, C. Linde, D. J. van Veldhuisen, J. Brugada, et al.
The European cardiac resynchronization therapy survey
Eur. Heart J.,
October 2, 2009;
30(20):
2450 - 2460.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Boveda, E. Marijon, S. Jacob, P. Defaye, J. B. Winter, A. Bulava, D. Gras, J. P. Albenque, N. Combes, D. Pavin, et al.
Incidence and prognostic significance of sustained ventricular tachycardias in heart failure patients implanted with biventricular pacemakers without a back-up defibrillator: results from the prospective, multicentre, Mona Lisa cohort study
Eur. Heart J.,
May 2, 2009;
30(10):
1237 - 1244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O.-A. Breithardt and G. Breithardt
Quest for the Best Candidate: How Much Imaging Do We Need Before Prescribing Cardiac Resynchronization Therapy?
Circulation,
February 21, 2006;
113(7):
926 - 928.
[Full Text]
[PDF]
|
 |
|
|